Zhejiang East-Asia Pharmaceutical (605177.SH): Quetiapine raw material drug obtains South Korean raw material drug registration certificate.

Zhejiang East-Asia Pharmaceutical (605177.SH) announced that it has recently received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (MFDS). Mosapride has a dual regulatory effect of promoting stomach motility and inhibiting excessive stomach motility, and can be used to treat symptoms such as poor appetite, nausea, vomiting, belching, abdominal distension, bowel sounds, abdominal pain, diarrhea, and constipation caused by gastrointestinal motility disorders. According to relevant data, the national sales of mosapride maleate formulations are expected to be approximately 372 million yuan in 2024. The company's mosapride raw material drug obtaining the South Korean raw material drug registration certificate marks that the company's mosapride raw material drug has obtained access qualifications in South Korea, which will have a positive impact on the company's expansion in the South Korean pharmaceutical market, thus promoting the sales of the company's mosapride raw material drug in other overseas markets.